AbbVie's oral CGRP-subject antagonists reached the clinical end of Phase 3.

Migraine is a complex chronic disease characterized by headache and neurological and autonotic neurological symptoms.
high incidence rate, affecting more than 1 billion people worldwide, is the world's highest cause of disability among people under the age of 50.
migraines have a substantial impact on many aspects of an individual's life during and between seizures due to the untimely and volatile frequency and severity of seizures.
daily activities, work, school and personal relationships are negatively affected, resulting in a significant burden on migraine sufferers, their family and friends.
Atogepant is an oral-given CGRP-subject antagonist specifically developed for preventive treatment of migraines.
CGRP and its subjects are expressed in the nervous system regions associated with migraine pathophysiology.
that CGRP levels increase during migraine attacks, and selective CGRP-subject antagonists can benefit migraine patients clinically.
Atogepant molecular structure (Photo: PubChem) In a multicenter, randomized double-blind, placebo-controlled, parallel group of Phase 3 clinical trials called ADVANCE, 910 patients with 4 to 14 days of migraine seizures per month were randomly assigned to one of four treatment groups, receiving 10 mg, 30 mg, or 60 mgatogepant or placebo therapy.
efficacy analysis was based on improved intent therapy (mITT) populations with 873 patients.
test results showed that all atogepant dose groups reached the main endpoint.
the average number of migraine days decreased by 3.69/3.86/4.2 days in patients in the 10 mg/30 mg/60 mg dose group, significantly better than the 2.48 days in the placebo group (p.lt;0.0001).
the trial also reached a critical secondary endpoint, with 55.6%/58.7%/60.8% of patients with an average migraine attack day reduction of 50% per month and 29.0% in the placebo group (p.lt;0.0001) during the 12-week trial.
" Migraine attacks can be debilitating, but they are a treatable disease," said Dr. Thomas J. Hudson, senior vice president of research and development and chief scientific officer at AbbVie.
" Reference: abbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention. Retrieved July 29, 2020, from the original standard express. The number of seizures decreased by 50% in patients with more than half migraines, and AbbVie's oral CGRP-subject antagonists reached phase 3 clinical endpoints: